Clinical evaluation of methoximorpholino-doxorubicin (FCE 23762) in dogs with spontaneous malignancies.

Abstract

We conducted a clinical evaluation of FCE 23762, a methoxymorpholino analog of doxorubicin, in 48 dogs with metastatic, nonresectable, or chemotherapy-resistant spontaneous malignancies at an initial dosage of 50-60 microg/kg IV every 3 weeks. Clinical evidence of toxicity was minimal; 6 dogs developed grades I, II, and III hematologic toxicities after the 1st treatment, and 1 dog developed grade II gastrointestinal toxicity. One dog became pancytopenic 4 months after discontinuation of FCE 23762. No other adverse effects were noted. Partial or complete remissions were observed in 32% of the dogs. Responses were observed both in previously untreated dogs and in those that had received prior chemotherapy, including doxorubicin. FCE 23762 is a promising new antineoplastic agent that can be used safely in dogs with cancer; doses higher than those used in this study may be used eventually in practice.

• Authors: S E Sheafor, C G Couto, H Ward, C Essinger, S J Nicol
• Journal: Journal of veterinary internal medicine (J Vet Intern Med) 2000 Jan-Feb Vol. 14 Issue 1 Pg. 86-9 ISSN: 0891-6640 [Print] United States
• PMID: 10668822 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibiotics, Antineoplastic
• methoxy-morpholinyl-doxorubicin
• Doxorubicin

Topics

• Animals
• Antibiotics, Antineoplastic (administration & dosage, pharmacology, therapeutic use)
• Dog Diseases (drug therapy, pathology)
• Dogs
• Dose-Response Relationship, Drug
• Doxorubicin (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
• Female
• Male
• Neoplasms (drug therapy, veterinary)
• Treatment Outcome